人間におけるシンバスタチン依存性プラーク安定化の基礎として,機能的に結合されたサイクロオキシゲナーゼ-2/プロスタグランジンEシンタゼを抑制する
Francesco Cipollone1, Maria Fazia, Annalisa Iezzi
1Department of Medicine and Aging, School of Medicine, University of Chieti G. d'Annunzio, Chieti, Italy.
Circulation
|March 26, 2003
まとめ
シムバスタチンは炎症を軽減し,大動脈板内のマクロファージにおけるCOX-2/mPGES発現を抑制します. この作用は,マトリックスメタルプロテインアース (MMP) 誘発の破裂を軽減することにより,プラークの安定化に貢献します.
科学分野:
- 心血管科学の研究について
- 薬理学 薬理学とは
- 分子生物学は分子生物学である.
背景:
- スタチンは,メタルプロテインアース (MMP) の活性を下げることで,動脈硬化性プラークを安定させます.
- スタチン誘発性プラーク安定化の基礎となる分子機構は,完全に理解されていません.
- サイクロオキシゲネーゼ-2 (COX-2) とマイクロソーマルPGEシンタゼ (mPGES) の強化された発現は,MMP活性とプラーク破裂と相関しています.
研究 の 目的:
- 炎症性細胞の浸透に対するシンバスタチンの効果を調査する.
- ヒトの頸動脈板におけるCOX-2/mPGESおよびMMPの発現にシムバスタチンの影響を決定する.
主な方法:
- カロチド狭窄症の患者で,シンバスタチンとダイエット,またはダイエットのみのランダム化試験.
- 炎症性細胞 (マクロファージ,Tリンパ球),COX-2/mPGES,MMP,脂質,酸化LDL,およびコラーゲンを含むプラーク組成の分析.
- 技術には,免疫細胞化学,ウエスタン・ブラット,RT-PCR,ジモグラフィーが含まれていました.
主要な成果:
- シムバスタチン治療は,プラーク内のマクロファージ,Tリンパ球,HLA-DR+炎症細胞を著しく減少させました.
- シムバスタチンはCOX-2/mPGESとMMPの発現と活性を低下させた.
- シムバスタチン群のプラークは,コラーゲンの増加と脂質/酸化LDLの含有量の減少を示した.
- In vitroでは,メバロナートは,シンバスタチンによるCOX-2/mPGESの抑制を逆転させた.
結論:
- シムバスタチンは,炎症を効果的に軽減し,プラークマクロファージにおけるCOX-2/mPGES発現を抑制します.
- シムバスタチンによるCOX-2/mPGESの抑制は,プラークの安定化に寄与する.
- このメカニズムは,MMP誘発のプラーク破裂の抑制を含む可能性があります.
さらに関連する動画
関連する概念動画
GPCRs Regulate Adenylyl Cylase Activity
6.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
1.4K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.4K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.3K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K


